Pharmacokinetics of tauromustine in cancer patients

[1]  P. Gunnarsson,et al.  Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU) , 1988, Investigational New Drugs.

[2]  H. Hansen,et al.  A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU). , 1987, European journal of cancer & clinical oncology.

[3]  J. S. Macpherson,et al.  Phase I study of TCNU, a novel nitrosourea. , 1987, European journal of cancer & clinical oncology.

[4]  J. Stuart,et al.  A High Pressure Liquid Chromatographic Procedure for Monitoring: 1-(2‐Chloroethyl)-3-(4-trans-methylcyclohexyl)-1‐nitrosourea Levels in Body Fluids , 1982, Therapeutic drug monitoring.

[5]  A. Gouyette,et al.  Stability and preliminary pharmacokinetic studies of 1-(2-chloroethyl)-3-[1-(5'-paranitrobenzoyl-2',3'-isopropylidene)-alpha, beta-D-ribofuranosyl]-1-nitrosourea (RFCNU), a nonimmunosuppressive nitrosourea. , 1979, Cancer treatment reports.

[6]  N. Bleehen,et al.  Clinical pharmacokinetics of oral CCNU (Lomustine) , 2004, Cancer Chemotherapy and Pharmacology.

[7]  H. Hansen,et al.  In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[8]  G. Pratesi,et al.  Effects of tauromustine, a water-soluble nitrosourea compound on NMU-1 murine lung tumor. , 1989, Oncology.

[9]  P. Gunnarsson,et al.  Determination of tauromustine, a nitrosourea-based antitumour agent, in plasma by high-performance liquid chromatography. , 1988, Journal of chromatography.

[10]  H. S. Lin,et al.  Chloroethylnitrosourea cancer chemotherapeutic agents. , 1982, Advances in pharmacology and chemotherapy.